Skip to content
value.today

Tracon Pharmaceuticals Inc

Formerly Lexington Pharmaceuticals, Inc.

Total raised
$58 M
4 rounds on record
Latest round
$39 M
Mar 2018
First round on record
Mar 2010
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Tracon Pharmaceuticals Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2018$39 MNo. 4$10 to $50 million

Tracon Pharmaceuticals Inc: Raise no. 4, Mar 2018

Investors in this round

11 investors had bought by the notice of Apr 10, 2018: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Tracon Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$39 M of $76 M offered; $37 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,985,506
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles P. Theuer · Executive Officer, Director
  • Patricia L. Bitar · Executive Officer
  • J. Rainer Twiford · Director
  • Martin L. Mattingly · Director
  • Paul Rainer Walker · Director
  • Stephen Rainer Worland · Director
  • Ted Rainer Wang · Director
  • William L. Larue · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Angel Pond Capital LLC (CRD 287761) · New York, New YorkSold in all US states, and outside the US
  • LifeSci Capital (CRD 168404) · New York, New YorkSold in all US states, and outside the US

Remarks in the notice

  • On the amounts: “"""Total Offering Amount"" includes amounts receivable by the Issuer upon the exercise of certain warrants to purchase the Issuer's Common Stock (assuming no cashless exercise)."”

Signed by Patricia L. Bitar, Cfo. Source: SEC Form D, newest notice filed Apr 10, 2018. Read the notice at the SEC.

equity, optionsSEC
Mar 2017$1 MNo. 3Under $2 million

Tracon Pharmaceuticals Inc: Raise no. 3, Mar 2017

Investors in this round

1 investor had bought by the notice of May 10, 2017: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Tracon Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $21 M offered; $20 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles P. Theuer · Executive Officer, Director
  • H Casey Logan · Executive Officer
  • Patricia L. Bitar · Executive Officer
  • J. Rainer Twiford · Director
  • Martin Casey Mattingly · Director
  • Paul Rainer Walker · Director
  • Stephen Rainer Worland · Director
  • William Casey Larue · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Patricia L. Bitar, Cfo. Source: SEC Form D, newest notice filed May 10, 2017. Read the notice at the SEC.

equitySEC
Mar 2011$17 MNo. 2$10 to $50 million

Tracon Pharmaceuticals Inc: Raise no. 2, Mar 2011

Investors in this round

15 investors had bought by the notice of Apr 1, 2011: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Tracon Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$17 M of $25 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bonne Adams · Executive Officer
  • Bryan Leigh · Executive Officer
  • Charles P. Theuer · Executive Officer, Director
  • Sharon Real · Executive Officer
  • Hironori Rainer Hozoji · Director
  • J. Rainer Twiford · Director
  • Kenji Rainer Harada · Director
  • Myoung-Ok Rainer Kwon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Amount sold includes cash proceeds and conversion of $2,500,000 of principal/interest under certain promissory notes into equity at the purchase price paid by cash investors. Another ~$8 million in cash may be invested at the option of certain investors.”

Signed by Charles P. Theuer, President and CEO. Source: SEC Form D, newest notice filed Apr 1, 2011. Read the notice at the SEC.

equitySEC
Mar 2010$2 MNo. 1Under $2 million

Tracon Pharmaceuticals Inc: Raise no. 1, Mar 2010

Investors in this round

10 investors had bought by the notice of Oct 25, 2010: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Tracon Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
$50,000
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$39,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bonne P. Adams · Executive Officer
  • Bryan E. Leigh · Executive Officer
  • Charles P. Theuer · Executive Officer, Director
  • Sharon P. Real · Executive Officer
  • Timothy M. Hofer · Executive Officer
  • Bertrand C. Liang · Director
  • J. Jay Lobell · Director
  • J. Rainer Twiford · Director
  • James E. Cantrell · Director
  • John R. Bolton · Director
  • William C. Comer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Paramount BioCapital, Inc. (CRD 29795) · New York, New YorkSold in AL, AZ, CO, FL, NJ, NY, OH, PA, VA

Signed by Timothy M. Hofer, Secretary. Source: SEC Form D and 1 amendment, newest notice filed Oct 25, 2010. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Tracon Pharmaceuticals Inc chose not to state its revenue in its newest notice of a funding round (Apr 2018).

    SEC Form D · Apr 2018

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2018

That is all the official record says: Tracon Pharmaceuticals Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in Tracon Pharmaceuticals Inc
InvestorKindAmountRoundRoleSource
Brookline Tracon Investment Fund II, LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
CSA Biotechnology Fund II, LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
JAFCO Super V3 Investment Limited PartnershipFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Nea 14 GP, LTDCompanynot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
NEA Partners 14, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
New Enterprise Associates 14, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2015)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 15 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Tracon Pharmaceuticals Inc
NameRoleNamed in
Charles P. TheuerExecutive officerApr 2018
Patricia L. BitarExecutive officerApr 2018
H Casey LoganExecutive officerMay 2017
Bonne AdamsExecutive officerApr 2011
Bryan LeighExecutive officerApr 2011
Sharon RealExecutive officerApr 2011
Bonne P. AdamsExecutive officerOct 2010
Bryan E. LeighExecutive officerOct 2010
Sharon P. RealExecutive officerOct 2010
Timothy M. HoferExecutive officerOct 2010
Charles P. TheuerDirectorApr 2018
J. Rainer TwifordDirectorApr 2018
Martin L. MattinglyDirectorApr 2018
Paul Rainer WalkerDirectorApr 2018
Stephen Rainer WorlandDirectorApr 2018
Ted Rainer WangDirectorApr 2018
William L. LarueDirectorApr 2018
Martin Casey MattinglyDirectorMay 2017
William Casey LarueDirectorMay 2017
Hironori Rainer HozojiDirectorApr 2011
Kenji Rainer HaradaDirectorApr 2011
Myoung-Ok Rainer KwonDirectorApr 2011
Bertrand C. LiangDirectorOct 2010
J. Jay LobellDirectorOct 2010
James E. CantrellDirectorOct 2010
John R. BoltonDirectorOct 2010
William C. ComerDirectorOct 2010